Diametric Capital, LP Exelixis, Inc. Transaction History

Diametric Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $200,711 - $238,127	9,951 New	9,951 $236,000
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $259,181 - $337,800	-12,539 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $3,901 - $6,498	237 Added 1.93%	12,539 $298,000
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $177,886 - $268,183	12,302 New	12,302 $212,000
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $217,373 - $284,204	-11,483 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $225,066 - $284,319	11,483 New	11,483 $273,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.